Insights into the Control of Drug Release from Complex Immediate Release Formulations.

MCC NaCl disintegration dissolution pharmaceutical tablet porosity terahertz terahertz pulsed imaging wetting

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
23 Jun 2021
Historique:
received: 05 05 2021
revised: 16 06 2021
accepted: 17 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 3 7 2021
Statut: epublish

Résumé

The kinetics of water transport into tablets, and how it can be controlled by the formulation as well as the tablet microstructure, are of central importance in order to design and control the dissolution and drug release process, especially for immediate release tablets. This research employed terahertz pulsed imaging to measure the process of water penetrating through tablets using a flow cell. Tablets were prepared over a range of porosity between 10% to 20%. The formulations consist of two drugs (MK-8408: ruzasvir as a spray dried intermediate, and MK-3682: uprifosbuvir as a crystalline drug substance) and NaCl (0% to 20%) at varying levels of concentrations as well as other excipients. A power-law model is found to fit the liquid penetration exceptionally well (average R2>0.995). For each formulation, the rate of water penetration, extent of swelling and the USP dissolution rate were compared. A factorial analysis then revealed that the tablet porosity was the dominating factor for both liquid penetration and dissolution. NaCl more significantly influenced liquid penetration due to osmotic driving force as well as gelling suppression, but there appears to be little difference when NaCl loading in the formulation increases from 5% to 10%. The level of spray dried intermediate was observed to further limit the release of API in dissolution.

Identifiants

pubmed: 34201663
pii: pharmaceutics13070933
doi: 10.3390/pharmaceutics13070933
pmc: PMC8308816
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Biochim Biophys Acta. 2006 Jul;1758(7):858-67
pubmed: 16566893
Drug Dev Ind Pharm. 2003 Mar;29(3):289-97
pubmed: 12741610
Int J Pharm. 2018 Mar 1;538(1-2):188-214
pubmed: 29341913
AAPS PharmSciTech. 2014 Feb;15(1):149-60
pubmed: 24222269
PLoS One. 2015 Jan 24;10(1):e0116914
pubmed: 25617891
Materials (Basel). 2011 Oct 24;4(10):1861-1905
pubmed: 28824113
Drug Dev Ind Pharm. 1999 May;25(5):571-81
pubmed: 10219525
Pharm Res. 2008 Apr;25(4):853-60
pubmed: 17612794
AAPS PharmSciTech. 2007 Jul 13;8(3):E57
pubmed: 17915807
Pharm Res. 2017 May;34(5):890-917
pubmed: 28251425
J Control Release. 2011 Dec 20;156(3):345-54
pubmed: 21911016
Pharm Res. 2020 Mar 16;37(4):70
pubmed: 32185516
Am J Physiol Heart Circ Physiol. 2012 Mar 1;302(5):H1031-49
pubmed: 22058154
Eur J Pharm Sci. 2013 Mar 12;48(4-5):758-66
pubmed: 23348153
Chem Pharm Bull (Tokyo). 2008 Apr;56(4):598-601
pubmed: 18379117
J Pharm Sci. 2010 Apr;99(4):2070-9
pubmed: 19780132
J Control Release. 2004 Aug 11;98(2):295-305
pubmed: 15262420
J Pharm Sci. 2010 Aug;99(8):3462-72
pubmed: 20229597
J Pharm Sci. 2015 Oct;104(10):3440-3450
pubmed: 28739040
Int J Pharm. 2017 Jun 30;526(1-2):1-10
pubmed: 28400289
Pharm Res. 2017 May;34(5):929-940
pubmed: 27766463
Int J Pharm. 2015;486(1-2):268-86
pubmed: 25827903

Auteurs

Runqiao Dong (R)

Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, UK.

James C DiNunzio (JC)

Pharmaceutical Sciences, Merck, Rahway, NJ 07065, USA.

Brian P Regler (BP)

Pharmaceutical Sciences, Merck, Rahway, NJ 07065, USA.

Walter Wasylaschuk (W)

Pharmaceutical Sciences, Merck, Rahway, NJ 07065, USA.

Adam Socia (A)

Pharmaceutical Sciences, Merck, Rahway, NJ 07065, USA.

J Axel Zeitler (JA)

Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, UK.

Classifications MeSH